[Click eStock] "BodytechMed, Excellent Competitiveness in Diagnostic Kit Antibody Testing Sector"

[Asia Economy Reporter Hyungsoo Park] Research Alom evaluated Bodytech Med on the 15th, stating that it has secured excellent competitiveness in the diagnostic kit antibody diagnosis sector.

Choi Seonghwan, Chief Researcher at Research Alom, explained, "Bodytech Med's main product, the antibody diagnostic kit, uses high-sensitivity fluorescence instead of gold particles applied in other diagnostic devices," adding, "It shows sensitivity 10 to 100 times higher compared to other companies' products."

He continued, "The test accuracy reaches 90%, and results can be confirmed within 10 minutes," adding, "It has accuracy comparable to molecular diagnostic methods and competitiveness in terms of cost and time."

Researcher Choi also emphasized, "Most existing antibody diagnostic kits use qualitative rapid kits," stating, "They are easy to use but difficult to diagnose during the incubation period."

He analyzed, "Through point-of-care testing (POCT) devices, virus antibodies can be quantified from low concentrations," adding, "Early diagnosis is possible."

Researcher Choi introduced, "We have obtained export approval from the Ministry of Food and Drug Safety for two types of COVID-19 immune diagnostic kits and molecular diagnostic kits," and "Product registration with the U.S. FDA has been completed."

Bodytech Med is expected to begin full-scale product supply from the second quarter. It has already received approval and is supplying products to major markets including Brazil.

This content was produced with the assistance of AI translation services.